精神分裂症相互作用组衍生可再利用药物及两种候选药物的随机对照试验
针对精神分裂症治疗需求未满足的问题,研究者开发了一种基于蛋白质相互作用网络的计算方法,对比疾病与药物的转录组调控,得到12种候选药物,其中9种有额外支持证据。研究者根据依从性和副作用特征选择2种候选药物,正在对精神分裂症或分裂情感性障碍患者开展辅助性随机对照试验。
要点
- 计算分析得到12种候选药物,其中9种的目标网络富集于精神分裂症病因相关通路或相关基因。
- 根据依从性和副作用特征选择2种候选药物进行辅助性随机对照试验。
- 试验纳入常规治疗后精神病性特征未完全缓解的精神分裂症或分裂情感性障碍患者。
核心结论
- 整合计算分析可识别和排序用于临床试验的药物,并可在获得新数据后迭代。
- 该方法未来可扩展至疾病亚型特异性药物发现,并应推广至其他精神疾病。
研究设计与样本
- 研究为计算分析,基于基因组、转录组和药理学数据,研究靶向精神分裂症蛋白质相互作用网络中蛋白质的药物。
- 通过对比疾病与药物的转录组调控,得到12种候选药物,其中9种有额外支持证据。
- 选择2种候选药物开展辅助性随机对照试验,纳入常规治疗后精神病性特征未完全缓解的精神分裂症或分裂情感性障碍患者。
主要发现
- 计算分析得到12种候选药物,其中9种的目标网络富集于精神分裂症病因相关通路或与精神分裂症致病相似疾病相关的基因。
- 根据可能依从性和副作用特征,从候选药物中选择2种进行辅助性随机对照试验。
- 所选候选药物已有先前安全性批准,因此无需进行耗时的1期和2期研究。
关键数值与推荐
- 候选药物为美国食品药品监督管理局批准或已进入临床试验后期阶段的药物或化合物。
- 12种候选药物中9种有额外支持证据,即目标网络富集于精神分裂症病因相关通路或与精神分裂症致病相似疾病相关的基因。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is a substantial unmet need for effective and patient-acceptable drugs to treat severe mental illnesses such as schizophrenia (SZ). Computational analysis of genomic, transcriptomic, and pharmacologic data generated in the past 2 decades enables repurposing of drugs or compounds with acceptable safety profiles, namely those that are U.S. Food and Drug Administration approved or have reached late stages in clinical trials. We developed a rational approach to achieve this computationally for SZ by studying drugs that target the proteins in its protein interaction network (interactome). This involved contrasting the transcriptomic modulations observed in the disorder and the drug; our analyses resulted in 12 candidate drugs, 9 of which had additional supportive evidence whereby their target networks were enriched for pathways relevant to SZ etiology or for genes that had an association with diseases pathogenically similar to SZ. To translate these computational results to the clinic, these shortlisted drugs must be tested empirically through randomized controlled trials, in which their previous safety approvals obviate the need for time-consuming phase 1 and 2 studies. We selected 2 among the shortlisted candidates based on likely adherence and side-effect profiles. We are testing them through adjunctive randomized controlled trials for patients with SZ or schizoaffective disorder who experienced incomplete resolution of psychotic features with conventional treatment. The integrated computational analysis for identifying and ranking drugs for clinical trials can be iterated as additional data are obtained. Our approach could be expanded to enable disease subtype-specific drug discovery in the future and should also be exploited for other psychiatric disorders.
引用
- Ganapathiraju MK, Bhatia T, Deshpande S, et al. Schizophrenia Interactome-Derived Repurposable Drugs and Randomized Controlled Trials of Two Candidates. Biol Psychiatry. 2024. PMID: 38950808. doi:10.1016/j.biopsych.2024.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。